Home Breast Cancer Biomarkers Breast Cancer Biomarker Panel: ER, PR, HER2, Ki-67, Genomic Tests, and Tumor...

Breast Cancer Biomarker Panel: ER, PR, HER2, Ki-67, Genomic Tests, and Tumor Profile

By
Vita Library
-
29
Understand a breast cancer biomarker panel: ER, PR, HER2, Ki-67, genomic tests, mutation testing, score meaning, and how results guide treatment.

A breast cancer biomarker panel is not one universal blood test. It is the combined set of pathology and molecular tests used to describe what is driving a breast tumor and which treatments are most likely to help. The core tissue markers are estrogen receptor (ER), progesterone receptor (PR), and HER2. Ki-67 may add information about cell proliferation in selected settings, while genomic assays such as Oncotype DX, MammaPrint, EndoPredict, Prosigna, or Breast Cancer Index answer narrower questions about recurrence risk or treatment benefit in defined groups. Additional tumor tests—such as PIK3CA, ESR1, PD-L1, or germline BRCA1/2 testing—may become relevant depending on stage and subtype. The useful way to read a “panel” is therefore marker by marker. Each result has its own specimen requirements, scoring system, clinical purpose, and limitations; no single number summarizes the whole tumor.

  • ER, PR, and HER2 are standard breast tumor biomarkers because they directly influence major treatment choices.
  • ER staining of at least 1% is considered positive under current ASCO/CAP guidance; 1%–10% is reported as ER Low Positive.
  • HER2 IHC 3+ is positive; IHC 2+ is equivocal and usually requires in situ hybridization to determine amplification status.
  • Ki-67 estimates proliferation, but intermediate values are less reproducible and should not be treated as a stand-alone chemotherapy rule.
  • Genomic assays are used only in defined early-stage settings and are not interchangeable with ER, PR, HER2, stage, or tumor grade.

Table of Contents

What a Breast Cancer Biomarker Panel Includes

The foundation of breast cancer profiling is the pathology report from a core biopsy or surgical specimen. Histology identifies the cancer type and grade; ER and PR immunohistochemistry measure hormone-receptor protein in tumor-cell nuclei; HER2 testing measures HER2 protein expression and, when needed, ERBB2 gene amplification. These markers classify tumors into clinically meaningful groups such as hormone-receptor positive/HER2-negative, HER2-positive, or triple-negative.

A panel may then expand based on the clinical question. Ki-67 measures the proportion of tumor cells staining for a proliferation-associated nuclear protein. It can help characterize how actively a tumor is dividing, but its clinical utility is more limited than ER, PR, and HER2. The International Ki67 Working Group has emphasized standardized handling and scoring and notes that very low values around 5% or less and high values around 30% or more are more reliable for prognosis in selected ER-positive/HER2-negative early cancers than values in the middle.

Genomic expression assays analyze RNA from the tumor rather than simply counting protein-positive cells. Tests such as Oncotype DX, MammaPrint, EndoPredict, Prosigna, and Breast Cancer Index were developed for specific early-stage populations. Some estimate distant-recurrence risk, some help estimate chemotherapy benefit, and some address late recurrence or extended endocrine therapy. They are not a general “cancer severity” score and should not be ordered outside a setting where the result can change a real decision.

Advanced breast cancer may require additional molecular testing. Examples include ESR1 for endocrine resistance, PIK3CA and AKT-pathway alterations for targeted therapy, germline BRCA1/2 for hereditary risk and PARP-inhibitor eligibility, and PD-L1 or other markers in selected triple-negative disease. Which tests belong in the profile changes with disease stage, prior treatment, and new drug approvals.

ER and PR Results: Hormone Receptor Status

ER is the most important predictive marker for endocrine therapy. Immunohistochemistry reports the percentage of invasive tumor-cell nuclei that stain and may also report staining intensity. Under ASCO/CAP guidance, tumors with at least 1% ER-positive nuclei are considered ER positive. Tumors with 1%–10% staining should be reported as ER Low Positive because evidence for endocrine sensitivity is less certain than it is for strongly ER-positive disease. A 0% or less-than-1% result is ER negative when controls are valid.

The ER test does more than label a tumor “positive.” A result of 90% strong staining represents very different biology from 2% weak staining, even though both cross the formal positivity threshold. Recent systematic reviews suggest endocrine therapy can still be associated with improved outcomes in ER-low early breast cancer, but the evidence is largely observational and these tumors often share features with ER-negative disease. That is why the low-positive category deserves explicit discussion rather than being hidden inside a single yes/no field.

PR is also measured by IHC. PR expression often reflects an active estrogen-signaling pathway and can contribute prognostic context, but ER remains the primary marker used to determine whether endocrine therapy is appropriate. An ER-positive/PR-negative tumor may be biologically different from an ER-positive/PR-positive tumor without automatically becoming “hormone resistant.”

Preanalytic quality matters. Delayed fixation, poor fixation, scant tumor, or an unusual result that conflicts with the tumor’s histology can affect interpretation. Laboratories use internal and external controls, and pathologists may repeat testing when a low or negative result appears technically questionable or biologically discordant.

HER2 Testing and HER2-Low or Ultralow Categories

HER2 testing begins with immunohistochemistry in many laboratories. IHC 0 and 1+ are not HER2-positive under the classic ASCO/CAP definition. IHC 2+ is equivocal and generally requires in situ hybridization (ISH), while IHC 3+ is HER2 positive when the required complete, intense membrane-staining pattern is present in more than 10% of invasive tumor cells. ISH evaluates ERBB2 gene amplification and is interpreted with copy-number and ratio rules.

The full HER2 test interpretation matters because antibody-drug conjugates expanded the clinical importance of low-level HER2 expression. “HER2-low” is commonly used for IHC 1+ or IHC 2+/ISH-negative tumors in treatment settings supported by trials and regulatory approvals. In 2025, the FDA also approved trastuzumab deruxtecan for a defined group with hormone-receptor-positive, metastatic HER2-ultralow disease, described for that indication as IHC 0 with membrane staining, after progression on endocrine therapy.

These newer treatment categories do not erase the classic HER2-positive versus HER2-negative framework. A tumor that is IHC 1+ is still not HER2-amplified simply because it may be called HER2-low. Likewise, “ultralow” does not mean the tumor has a new gene amplification category. It describes very low protein expression relevant to a specific therapeutic context.

Small differences at the 0/1+ boundary can be challenging. Preanalytic handling, antibody platform, staining quality, heterogeneity, and pathologist interpretation all matter. If a later treatment depends on distinguishing no visible membrane staining from faint incomplete staining, review or repeat testing on an appropriate specimen may be clinically important.

Ki-67, Tumor Grade, and Proliferation

Ki-67 is a nuclear protein expressed in cycling cells. A pathology report gives a percentage intended to estimate how many tumor cells are proliferating. Higher values usually correlate with faster growth and, within some breast cancer subtypes, worse prognosis. The difficulty is reproducibility: the result can change with tissue handling, staining methods, the area selected for scoring, and how observers count heterogeneous “hot spots.”

The International Ki67 Working Group concluded that analytical validity can be improved with standardized methods, but broad clinical utility remains limited. For anatomically favorable ER-positive/HER2-negative stage I–II disease, values at the extremes—about 5% or lower and 30% or higher—can support prognosis estimation. Intermediate values should not be forced into a universal good-versus-bad cutoff.

Ki-67 is not the same as histologic grade. Grade incorporates tubule formation, nuclear atypia, and mitotic activity. Nor is Ki-67 the same as a multigene recurrence score. Those measures are correlated because they all capture aspects of tumor biology, but they are generated differently and have different validation evidence.

This distinction matters when results disagree. A grade 2 tumor with Ki-67 of 18% and a low genomic recurrence score is not “inconsistent” simply because the numbers are not identical. The clinician should ask which measurement has evidence for the treatment decision at hand. If the question is whether a postmenopausal patient with certain ER-positive/HER2-negative early-stage disease can omit chemotherapy, an appropriately validated genomic assay may be more decision-specific than an intermediate Ki-67 value.

Genomic Tests and Recurrence-Risk Scores

Genomic assays measure patterns of gene expression in the tumor and convert them into a validated risk classification or score. They are most useful when standard clinical and pathology features leave a genuine treatment decision uncertain. ASCO guidance supports selected use of Oncotype DX, MammaPrint, Breast Cancer Index, EndoPredict, and Prosigna in defined ER-positive/HER2-negative early breast cancer populations, with age, menopausal status, and nodal involvement influencing which tests are appropriate.

The assays are not interchangeable. Oncotype DX has prospective randomized evidence that helps estimate chemotherapy benefit in important node-negative and selected node-positive settings. MammaPrint uses a different gene set and risk framework. EndoPredict combines a molecular score with tumor size and nodal status in EPclin and is primarily prognostic. Prosigna uses the PAM50 gene set to provide intrinsic subtype and a risk-of-recurrence score in defined postmenopausal populations. Breast Cancer Index is particularly relevant to late distant-recurrence risk and the potential benefit of extending endocrine therapy after about five years in selected patients.

A score should always be read in the context of the assay’s validated population. A “high risk” category on one test is not numerically comparable with “high risk” on another. Likewise, a score does not replace tumor size, nodes, grade, patient age, medical fitness, or preferences.

The most useful question before ordering any genomic assay is: “What choice will change if the result is low versus high?” If neither result would alter management, testing adds cost and complexity without clinical value. If the result could reasonably prevent unnecessary chemotherapy or clarify extended endocrine therapy, the assay may add substantial practical value.

Biomarkers That Become Important in Advanced Disease

Metastatic breast cancer often requires a new round of biomarker assessment because tumors evolve under treatment pressure. When feasible, a metastatic site may be biopsied to reconfirm ER, PR, and HER2. Discordance can occur between the original tumor and a recurrence, and current receptor status can affect therapy.

Blood-based circulating tumor DNA can provide another route to genomic profiling when an adequately sensitive assay is used. An ESR1 mutation can indicate acquired resistance to aromatase-inhibitor therapy and can now guide specific endocrine-treatment choices. PIK3CA mutations, AKT1 alterations, or PTEN loss may support pathway-targeted therapies under current indications. Germline BRCA1/2 testing is separate from tumor-only profiling because inherited variants affect both treatment eligibility and family risk.

Triple-negative breast cancer has its own testing needs. PD-L1 testing can determine eligibility for pembrolizumab-based therapy in appropriate metastatic settings, while germline BRCA testing may identify a hereditary driver and treatment option. HER2-low expression may also matter even though the tumor remains HER2-negative by classic amplification criteria.

A serum marker such as CA 15-3 or CA 27.29 is different from these predictive biomarkers. It may be followed as an adjunct in some metastatic patients, but it does not identify a drug target. Similarly, ctDNA quantity or mutation detection does not replace imaging and clinical assessment for every monitoring decision.

The panel therefore changes over time. Early-stage profiling focuses heavily on receptor status, HER2, anatomic risk, and selected genomic assays. Advanced-disease profiling increasingly focuses on current receptor status and actionable acquired mutations. Treating every stage with the same fixed “panel” risks both missing useful tests and ordering irrelevant ones.

How to Read the Whole Tumor Profile Without Mixing Up the Tests

Start with the question each result answers. ER and PR ask whether hormone-receptor signaling is present. HER2 asks whether the tumor has HER2 overexpression/amplification and, increasingly, whether low-level expression is relevant to an antibody-drug conjugate. Ki-67 estimates proliferation. Grade describes microscopic differentiation. Genomic assays estimate recurrence biology in defined early-stage settings. Somatic mutation testing looks for actionable alterations. Germline testing looks for inherited susceptibility.

Then check the specimen and date. A result from the original breast biopsy may not fully represent metastatic disease years later. Conversely, a blood ctDNA result may be falsely negative when tumor shedding is low, so a negative liquid-biopsy result can sometimes require tissue testing. Each technology has failure modes.

Next, separate prognostic information from predictive information. Prognostic markers estimate the chance of an outcome such as recurrence. Predictive markers identify whether one treatment is more or less likely to help. Some assays provide both types of information in specific contexts, but a prognostic high-risk result should not automatically be described as proof of chemotherapy benefit.

Finally, ask whether the result is actionable now. A beautifully detailed molecular report can contain variants that are biologically interesting but not treatment-changing. The best tumor profile is not the one with the most tests; it is the one that answers the decisions actually facing the patient.

When reports appear contradictory, a multidisciplinary review can reconcile pathology, imaging, stage, prior therapy, and molecular data. That approach prevents a single percentage or genomic score from being given more authority than its evidence supports.

When a biomarker panel should be repeated

A breast cancer profile is a snapshot of a particular specimen at a particular time. It should not automatically be treated as permanent. Repeating selected biomarkers can be useful when there is a new recurrence or metastasis, when the original tissue was technically limited, or when a result conflicts with the tumor’s morphology and clinical behavior. ER, PR, and HER2 can change after treatment or differ between metastatic sites. A current biopsy can therefore create a different treatment path from an old primary-tumor report.

Repeat testing should be selective rather than automatic. Ki-67 is affected by preanalytic conditions and reader variability, so repeating it simply to chase a slightly different percentage rarely resolves a treatment decision. Genomic recurrence assays are also validated for specific early-stage questions and generally are not meant to be repeated on every specimen as the disease evolves. By contrast, metastatic molecular profiling may need to be updated because acquired mutations can emerge under treatment pressure. Plasma ctDNA can sometimes detect those changes without another tissue biopsy, but a negative blood result may need tissue confirmation when tumor shedding is low.

A useful way to judge any repeat test is to ask three questions: Has the cancer or specimen changed? Could the marker realistically change? Would a different result alter treatment? If the answer to the last question is no, more testing may create noise rather than clarity.

The same principle applies to apparently conflicting results. An ER-positive primary tumor and an ER-negative metastasis are not “averaged” into an intermediate category. The clinical team reviews specimen quality, treatment history, and the biological plausibility of receptor conversion, then chooses the result most relevant to the current disease. A tumor profile is valuable because it guides a decision, not because it maximizes the number of measurements on a report.

A final safeguard is to read the test date and treatment context before comparing reports. A genomic assay ordered on an untreated early tumor, a receptor panel from a post-treatment surgical specimen, and a ctDNA panel from metastatic disease answer different questions. Apparent contradictions often disappear once the specimen and timing are clear. If a marker is being used to choose a drug, ask whether that marker was measured on tissue representative of the disease being treated now and whether the assay is validated for that decision. This simple check prevents old, technically limited, or context-mismatched results from being given more weight than current evidence supports.

References

Disclaimer

This article is educational and does not interpret any individual pathology or genomic report. Breast cancer biomarker results must be integrated with stage, pathology, prior treatment, medical history, and current treatment indications by the patient’s oncology team.

RELATED ARTICLESMORE FROM AUTHOR